Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

The safety profile of fingolimod has been well characterized in this large combined trial population. Although infrequent SAEs can occur, there is no increased risk of infections, malignancies or serious cardiovascular events versus placebo.